Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Use of Therapeutic Monoclonal Antibodies Increasing in Europe - Despite high therapy costs and drug format limitations, the popularity of monoclonal antibodies (mAbs) is on the rise
Use of Therapeutic Monoclonal Antibodies Increasing in Europe

 

PRZOOM - /newswire/ - London, United Kingdom, 2008/09/15 - Despite high therapy costs and drug format limitations, the popularity of monoclonal antibodies (mAbs) is on the rise.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Physicians are increasingly adopting mAbs because of their superior side effect profile, and continued research is expected to yield more innovative products.

New analysis from Frost & Sullivan (pharma.frost.com), European Therapeutic Monoclonal Antibody Markets, finds that the markets earned revenues of $7.9 billion in 2007 and estimates this to reach $22.2 billion in 2014.

"A strong R&D pipeline along with expanding applications of mAbs in new therapeutic and disease areas will accelerate market growth," notes Frost & Sullivan Senior Research Analyst Arun A.K. "The increasing number of alliances between pharma and biotech companies will advance research and technological initiatives, a factor key to the continued expansion of the market."

The financial success stories of top mAbs have attracted many companies and have resulted in mAbs being identified as a key growth area. Companies are relying on research to develop mAbs and associated technologies for commercial opportunities.

Market participants will however have to meet key challenges to take advantage of opportunities. Firstly, the public healthcare system is under tremendous pressure to support the therapy cost of mAbs. Due to their high costs, the target population for treatment is also likely to be limited. Moreover, the inherent challenges associated with development and manufacturing of mAbs is likely to remain high over the long term.

"High treatment costs and inherent limitations in the antibody format are constraining market expansion," explains Arun. "The heightened focus on small molecule drugs will also challenge the growth of this market over the next five to seven years."

Investing in research and moving manufacturing units to cheaper destinations will help overcome the high development costs associated with mAbs. Building a recognisable brand will enable companies to popularise mAbs and reduce the risk posed by alternate therapies in the future.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European therapeutic monoclonal antibody markets, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

European Therapeutic Monoclonal Antibody Markets is part of the Pharmaceutical and Biotechnology Growth Partnership Services Programme, which also includes research in the following markets: European Drug Delivery Markets, European Biosimilars Market and European CMO Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

European Therapeutic Monoclonal Antibody Markets
M28B

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Use of Therapeutic Monoclonal Antibodies Increasing in Europe

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Al Rowaad Advocates & Legal Consultants

Visit  1Click Games

Visit  Intrinsic Executive Search Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today